The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy
Abstract
Key Points: The intensified standard-of-care regimens for younger patients with MCL do not overcome the deleterious effects of TP53 mutations. MCLs with TP53 mutations should be considered for alternative frontline treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
TP53 mutations in human cancers: origins, consequences, and clinical use.
Olivier, M., Hollstein, M., & Hainaut, P. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001008 · Cited by 2,199 · cited 1×
“The explanation for this difference may relate to the dominant negative effect of someTP53mutations: although some mutated forms of p53 disrupt the function of the entire p53 protein-tetramer, deletions only reduce the amount of transcribed p53, and thus may affects the protein function to a lesser degree.(27) Further…”
BackgroundTargeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma
Wang, M. L., Rule, S., Martin, P., Goy, A., Auer, R., Kahl, B. S., Jurczak, W., Advani, R. H., Romaguera, J. E., Williams, M. E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1306220 · Cited by 1,685
Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
Woyach, J. A., Furman, R. R., Liu, T.-M., Ozer, H. G., Zapatka, M., Ruppert, A. S., Xue, L., Li, D. H.-H., Steggerda, S. M., Versele, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1400029 · Cited by 1,275 · cited 2×
“Of the remaining 319 patients, the median age was 57 years (29-65), 76% were male gender, 51% were MIPI high- or intermediate-risk, 18%”
BackgroundRahal, R., Frick, M., Romero, R., Korn, J. M., Kridel, R., Chun Chan, F., Meissner, B., Bhang, H.-E., Ruddy, D., Kauffmann, A., et al. (2014) · Nature Medicine · doi:10.1038/nm.3435 · Cited by 334
Jerkeman, M., Hutchings, M., Räty, R., Wader, K. F., Laurell, A., Kuitunen, H., Toldbod, H., Pedersen, L. B., Eskelund, C. W., Grønbæk, K., et al. (2016) · Blood · doi:10.1182/blood.v128.22.148.148 · Cited by 17 · cited 2×
“Of the remaining 319 patients, the median age was 57 years (29-65), 76% were male gender, 51% were MIPI high- or intermediate-risk, 18%”
BackgroundSelf-citation
Cited by
Campo, E., Jaffe, E. S., Cook, J. R., Quintanilla-Martinez, L., Swerdlow, S. H., Anderson, K. C., Brousset, P., Cerroni, L., de Leval, L., Dirnhofer, S., et al. (2022) · Blood · doi:10.1182/blood.2022015851 · Cited by 1,608
Nakhoda, S., Vistarop, A., & Wang, Y. L. (2023) · British Journal of Haematology · doi:10.1111/bjh.18418 · Cited by 104
Tessoulin, B., Descamps, G., Dousset, C., Amiot, M., & Pellat-Deceunynck, C. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00128 · Cited by 31
Metadata
- Authors
- Eskelund, C. W., Dahl, C., Hansen, J. W., Westman, M., Kolstad, A., Pedersen, L. B., Montano-Almendras, C. P., Husby, S., Freiburghaus, C., Ek, S., Pedersen, A., Niemann, C., Räty, R., Brown, P., Geisler, C. H., Andersen, M. K., Guldberg, P., Jerkeman, M., & Grønbæk, K.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2017-10-26
- Volume
- 130
- Issue
- 17
- Pages
- 1903-1910
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2749289906
- Cited by
- 407
- References
- 5
- FWCI
- 24.85
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy. https://app.cochat.ai/papers/10.1182/blood-2017-04-779736
- The paper
- Eskelund, C. W., Dahl, C., Hansen, J. W., Westman, M., Kolstad, A., Pedersen, L. B., Montano-Almendras, C. P., Husby, S., Freiburghaus, C., Ek, S., Pedersen, A., Niemann, C., Räty, R., Brown, P., Geisler, C. H., Andersen, M. K., Guldberg, P., Jerkeman, M., & Grønbæk, K. (2017). TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy. Blood. https://doi.org/10.1182/blood-2017-04-779736
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
